Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for 10x Genomics (TXG) over the last 4 years, with Q4 2025 value amounting to $25.2 million.

  • 10x Genomics' Change in Acquisitions & Divestments changed N/A to $25.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $125.2 million, marking a year-over-year increase of 38561.01%. This contributed to the annual value of $125.2 million for FY2025, which is 38561.01% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Change in Acquisitions & Divestments is $25.2 million.
  • Over the past 5 years, 10x Genomics' Change in Acquisitions & Divestments peaked at $93.3 million during Q1 2023, and registered a low of $1.2 million during Q3 2023.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $12.8 million (2024), whereas its average is $23.1 million.
  • Per our database at Business Quant, 10x Genomics' Change in Acquisitions & Divestments plummeted by 9198.94% in 2023 and then soared by 69800.62% in 2024.
  • Quarter analysis of 4 years shows 10x Genomics' Change in Acquisitions & Divestments stood at $7.7 million in 2022, then crashed by 47.46% to $4.1 million in 2023, then skyrocketed by 215.93% to $12.8 million in 2024, then soared by 96.75% to $25.2 million in 2025.
  • Its last three reported values are $25.2 million in Q4 2025, $50.0 million for Q3 2025, and $50.0 million during Q2 2025.